Therapeutic acridone and acridine compounds
CA 2473170 A1 · Owner: Kelland, Lloyd Royston · Inventors: Gowan, Sharon Michele; Read, Martin Anthony; Neidle, Stephen
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention pertains to certain acridone and acridine compounds of the formula (1) which inhibit telomerase, regulate cell proliferation etc. and/or treat cancer, proliferative conditions etc.: wherein either: (a) K is , =O, L is -H alpha single bond, beta is a double bond gamma is a single bond , (acridones); or (b) K is a 9-substituent, L is absent, alpha is a double bond, beta is a single bond, gamma is a double bond (acridines); and wherein: J1 is a 2- or 3-substituent; J2 is a 6- or 7-substituent; J1 and J2 are each a group of the formula -N(RN)-W, wherein: RN is a nitrogen substituent and is hydrogen, C1-7alkyl, C3-20heterocyclyl or C5-20aryl, and is optionally , substituted; …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 14, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 14, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 14, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.